Hikal starts construction of multiproduct API plant

Published: 28-Oct-2011
Manufacturing Ingredients

Will be operational by June 2012

Hikal, an Indian supplier of active ingredients and intermediates to the pharmaceutical industry, has started construction of a new multipurpose, multiproduct API plant, which will be operational by June 2012.

The flexible plant will be able to manufacture four APIs simultaneously under GMP and consists of two parallel streams running simultaneously with quick changeover capability.

The plant will also be able to accommodate 32 reactors with capacities ranging from 6m3 to 10m3, resulting in a total reactor volume of approximately 300m3.

A wide range of reactions will be carried out in the new plant, including nitration, liquid phase Oppenauer oxidation, Swern oxidation, Suzuki reaction, chiral synthesis, Mannich reaction, Friedel Craft reactions and more.

The firm says the reactors will be a combination of stainless steel and glass lined. Equipment for isolation and drying such as agitated nutsch filters, centrifuges and various types of dryers will also be installed.

Hikal has five manufacturing facilities in India at Maharashtra (Taloja and Mahad), Gujarat (Panoli) and Bangalore (Jigani), including an r&D centre and a dedicated contract research facility, Acoris Research, in Pune.

See more

You may also like

Ingredients

Hikal completes third US FDA audit in Bangalore

Read more
Indian ingredients manufacturer will ramp up new products under validation

Trending Articles

  1. Adragos Pharma acquires Sanofi's Maisons-Alfort sterile fill-finish facility to strengthen European injectables network Global CDMO Adragos Pharma has completed the acquisition of one of Europe's largest sterile injectables manufacturing sites from Sanofi in Maisons-Alfort, France, adding high-volume pre-filled syringe capabilities to its existing fill-finish operations in Switzerland and Livron
  2. Swiss Rockets collaborates with Lonza to advance Torqur’s oncology drug candidate bimiralisib into late-stage clinical development Lonza to provide cGMP manufacturing and technical support to advance bimiralisib into late-stage clinical development
  3. Marchesini Group at Interpack 2026 Sustainability, primary packaging, aseptic production, robotics and digital innovation at the heart of this edition
  4. L.B. Bohle hosts successful continuous manufacturing workshop in Brazil Focus on continuous wet granulation and drying for research, development and small-scale production
  5. Symbiosis completes full ICH climatic zone coverage with new stability chamber addition Sterile injectable CDMO Symbiosis Pharmaceutical Services has installed a 30°C stability chamber at its Stirling facility, completing its coverage of all four ICH-defined climatic zones and strengthening its commercial drug product supply capabilities for global markets

Upcoming event

Making Pharmaceuticals

21–22 April 2026 | Exhibition | Coventry, UK See all

You may also like

Ingredients

Hikal completes third US FDA audit in Bangalore

Indian ingredients manufacturer will ramp up new products under validation
Media

Acoris and c-LEcta to develop synthetic routes for chiral compounds

<p>Acoris Research, a subsidiary of Hikal, and c-LEcta, a German industrial biotech company, are to collaborate on developing synthetic routes for chiral compounds. The partnership combines the expertise of Acoris in process development and small-scale manufacturing with the biocatalysis technologies of c-LEcta.</p>
Ingredients

Hikal signs API contract manufacturing agreement with Pfizer

<p>Indian outsourcing company Hikal has completed a contract manufacturing agreement for supply of active pharmaceutical ingredients (APIs) with Pfizer. Terms of the agreement were not disclosed.</p>
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Accelerating the development of bispecific antibodies

Sherry Gu, Executive Vice President and CTO at WuXi Biologics, explains how the use of comprehensive tailored approaches can enhance bispecific antibody productivity, stability and quality while accelerating their delivery to market
Manufacturing

UK pharmaceutical manufacturers struggling to meet F-Gas compliance amid ageing cooling infrastructure

A new Aggreko report reveals that nearly all UK pharmaceutical manufacturers are facing barriers to upgrading cooling systems ahead of the accelerating F-Gas phase-down timeline
Manufacturing

Labtex - Fresh thinking and innovative solutions

Labtex states: "We are proud to provide unique solutions for laboratories and pilot plants across the UK"
Manufacturing

Nemera partners with Therakind to expand nasal drug delivery portfolio with DriDose dry powder platform

The manufacturer has announced a strategic partnership with UK pharmaceutical company Therakind to advance the DriDose intranasal dry powder platform, adding dry powder delivery capabilities to complement Nemera's existing liquid nasal formulation offering
Subscribe now